Cohort 1 will include 60 milligram (mg) of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.

Cohort 2 will include 120 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.

Cohort 3 will include 240 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.

Cohort 4 will include 480 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.

Cohort 5 will include 960 mg of GSK1363089. Dose escalation will be 100% if there is no drug-related AEs of Grade 2 or higher in previous cohort. Dose escalation will be 50% in case there is Grade 2 drug-related AEs in any previous cohort.

GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally

GSK1363089 (formerly XL880)

GSK Clinical Trials

This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of oral daily GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

GlaxoSmithKline

Herbal and Botanical

All Drugs and Chemicals

Cinnamon

Eligible subjects will receive GSK1363089 administered orally as a cinnamon-flavored liquid or as solid capsules with the starting dose for cohort 1 as 0.1 milligram/kilogram. Subjects in cohorts 1, 2, and 3A will receive GSK1363089 in the liquid formulation, while Cohorts 3B, 4, 5, 6, 7, and 8 will receive GSK1363089 in the solid capsule formulation.

GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid \[5 milligrams/milliliter\] or 1000 milligrams of GSK1363089 in 50 milliliters liquid \[20 milligrams/milliliter\]) or as solid capsules of 20, 100, and/or 200 milligrams.

GSK1363089

This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.

A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Carcinoma

Adenocarcinoma

Stomach Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Amino Acids

Tyrosine Kinase Inhibitors

Tyrosine

Dosing for first 5 days in every 14-day period.

This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.

Study of GSK1363089 in Metastatic Gastric Cancer

A Phase 2 Study of GSK1363089 (XL880) Administered Orally to Subjects With Metastatic Gastric Cancer

ORR is defined as the percentage of participants achieving best overall response of confirmed complete response (CR) or partial response (PR). Tumor response for participants with measurable lesions was assessed routinely (after 8 weeks of treatment and approximately every 8 weeks thereafter) using RECIST (version 1.0) criteria. The CR for target lesions was defined as disappearance of all target lesions (TLs) and the non-target lesions (NTLs). PR defined as at least 30% decrease in sum of the longest diameter (LD) of TLs, taking as reference baseline sum LD. The safety population included all participants who passed the screening criteria, enrolled in the study, and received at least 1 dose of study drug. Progressive disease will be used as PD.

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product whether or not it is considered drug related. This would include any side effect, injury, toxicity, sensitivity reaction, abnormal or worsening of a laboratory value, concurrent illness or sudden death. Pre-existing conditions that worsen during a study will be reported as AEs. SAE is an AE that results in death, is life-threatening, requires inpatient hospitalization or extends a current hospital stay, results in an ongoing or significant incapacity or interferes substantially with normal life functions, or causes a congenital anomaly or birth defect. Medical events that do not result in death, are not life-threatening, or do not require hospitalization may be considered SAEs if they put the participant in danger or require medical or surgical intervention to prevent one of the results listed above.

Participants systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured in mm of mercury (mmHg). These were collected after the participant sat quietly for at least five minutes. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The data for minimum (min) and maximum (max) post-baseline has been reported. Baseline is defined as the last non-missing record on or before first dose.

The pulse rate or heart rate (HR) for the participant's, were collected after the participant sat quietly for at least five minutes. Baseline evaluations were performed within 72 hours before the first dose. If performed within 24 hours of the first dose, baseline evaluations may serve as the pre-dose Day 1 visit evaluations. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. Baseline was defined as pre-dose, Day 1. The HR was measured in beats per minute (bpm). The min and max values have been reported.

The body temperature for the participants was assessed. These were collected after the participant sat quietly for at least five minutes. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. Baseline is defined as the last non-missing record on or before first dose.

The RR for the participant's, were collected after the participant sat quietly for at least five minutes. Baseline evaluations should be performed within 72 hours before the first dose. If performed within 24 hours of the first dose, baseline evaluations may serve as the pre-dose Day 1 visit evaluations. The change from Baseline was calculated by subtracting the Baseline values from the individual post-randomization values. Baseline was defined as pre-dose, Day 1 . The RR was measured in breaths per minute. Min and max post-baseline values are reported.

The data for serum chemistry parameters like albumin, alanine aminotransferase (ALT), alkaline phosphatase (ALP), amylase, aspartate amino transferase (AST), calcium, carbon dioxide, creatinine, gamma glutamyl transferase (GGT), glucose, blood urea nitrogen (BUN), chloride, free thyroxine, free triiodothyronine, lipase, phosphorous, potassium, sodium, total bilirubin, lactate dehydrogenase, total protein. The abnormal values have been reported wherein data for normal to low and normal to high has been reported.

The worst overall common terminology criteria for adverse events version 3.0 (CTCAE) grade (G) shift post baseline for each parameter was mentioned. Only worst case scenarios are presented. CTCAE grading is done as per intensity namely mild moderate severe life-threatening or Death. Analysis was done for Alanine aminotransferases, aspartate aminotransferases, Albumin, alkaline phosphatase, calcium, sodium, potassium, glucose, amylase, amylase, bilirubin, creatinine, phosphate, gamma glutamyl transferases (GGT), and triglycerol lipase. Worst Overall defined as worst post baseline out of normal range flag in the order of (high, low, normal) before 30 day follow up. Data for G3 and G4 is reported.

The hematology parameters worst case overall CTCAE grade shift post Baseline for each parameter was mentioned. CTCAE grading for version 3.0 was used and done as per intensity namely mild moderate severe life-threatening or Death. Participants were analyzed for basophils, eosinophils, erythrocytes, hematocrit, and monocytes were analyzed. Only the abnormal values were reported where normal to high and normal to low changes were reported. Worst Overall was defined as highest post baseline CTCAE grade before 30 day follow up.

The urinalysis parameters by worst case overall CTCAE grade shift post Baseline for each parameter were mentioned as per the CTCAE grading for version 3.0 and done as per intensity namely mild moderate severe life-threatening or Death. Participants were analyzed for abnormal values for bilirubin, ketones, nitrites, occult blood, pH, protein, specific gravity, and urobilinogen.

The worst overall grading by CTCAE version 3.0, was used to report the shift from baseline for hematology parameters namely hemoglobin, platelets and lymphocytes. The grades were namely G0, G1, G2, G3 and G4. The data for shifts from G2 to G3 and G0 to G4, mainly the shifts to higher grades G3 and G4 have been reported.

The number of participants who received concomitant medication during the study were reported. The data has been reported for the participants who have received subsequent chemotherapy, subsequent radiation therapy or other therapy.

Duration of PFS in months is defined as (Date of Disease Progression/Death - Date of First Dose + 1)/30.44. For participants who did not reach an event (disease progression or death) at the time of data cut-off, duration of PFS is censored at date of last available tumor assessment that is not 'Unable to Evaluate'. For participants who did not have any post-baseline tumor assessments, PFS was censored at Day 1. For any participants who received subsequent anti-cancer therapy, PFS will be right censored at the date of last adequate tumor assessment on or prior to the date of anti-cancer therapy initiation. For any participants who died or progressed after an extended lost-to-follow-up time (greater than 17 weeks), PFS was censored at the date of last adequate assessment prior to extended lost-to follow-up.

Duration of stable disease, was defined as the time between the date of first dose and death or disease progression, in participants whose best overall response was not progressive disease

It is defined as the number of participants achieving best overall response of confirmed CR or PR or stable disease (SD). It was assessed using RECIST criteria 1.0. The CR for target lesions was defined as disappearance of all TLs and the NTLs. PR is at least 30% decrease in sum of the LD of TLs, taking as reference baseline sum LD. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as a reference, the smallest sum LD since the treatment started.

Duration of OS is defined as (Date of Death \[due to any cause\]) minus Date of first dose. For the participants who were alive at the time of data cut-off, duration of overall survival was censored at the date of last contact. The upper value of the full range was censored observation.

The eligible participants in this arm were administered GSK1363089 at 240 mg per dosing day orally ( viz. foretinib solid capsules of 20, 100 and 200 mg) , as 5 days on and 9 days off cycle (no drug for 9-days) every 2 weeks for treatment period of 8 weeks. Participants fasted 2 hours before the dose, followed by a glass of water (after the intake of GSK1363089) and continued to fast 1 hour after each dose.

GSK1363089, Intermittent 5 and 9 Dosing

The eligible participants in this arm were administered GSK1363089 at 80 mg daily for treatment period of 8 weeks. Participants fasted 2 hours before the dose, followed by a glass of water (after the intake of GSK1363089) and continued to fast 1 hour after each dose. The enrollment in this cohort was started until the enrollment completion in the Intermittent 5 and 9 dosing arm.

GSK136308, Daily Dosing

The eligible participants in this arm were administered GSK1363089 at 240 mg per dosing day orally( viz. foretinib solid capsules of 20, 100 and 200mg) , as 5 days on and 9 days off cycle (no drug for 9-days) every 2 weeks for treatment period of 8 weeks. Participants fasted 2 hours before the dose, followed by a glass of water (after the intake of GSK1363089) and continued to fast 1 hour after each dose.

The eligible participants in this arm were administered GSK1363089 at 80 mg daily for treatment period of 8 weeks. Participants fasted 2 hours before the dose, followed by a glass of water (after the intake of GSK1363089) and continued to fast 1 hour after each dose. The enrollment in this cohort was started until the enrollment completion in the Intermittent 5 \& 9 dosing arm.

Total

Age, Continuous

Sex: Female, Male

Race (NIH/OMB)

GSK Response Center

Evaluable population included participants from safety population who had received atleast 75% of protocol mandated doses at treatment period, had BL and post BL tumor assessment, with no extended lost to followup (17 wks or more) or who had received atleast 75% of protocol mandated doses at treatment period and discontinued study drug due to PD.

Number of Participants With Objective Response Rate (ORR), of GSK1363089, Per- Response Evaluation Criteria in Solid Tumors (RECIST) Criteria Version 1.0

Any AE

Any SAE

The eligible participants in this arm were administered GSK1363089 at 240 mg per dosing day orally( viz. foretinib solid capsules of 20, 100 and 200 mg) , as 5 days on and 9 days off cycle (no drug for 9-days) every 2 weeks for treatment period of 8 weeks. Participants fasted 2 hours before the dose, followed by a glass of water (after the intake of GSK1363089) and continued to fast 1 hour after each dose.

Safety population included all participants who passed the screening criteria, enrolled in the study, and received at least 1 dose of study drug.

Number of Participants With Adverse Event (AE) and Serious Adverse Event (SAE)

SBP, max.post baseline

SBP, min.post baseline

DBP, max.post baseline

DBP, min.post baseline

Safety population. Only those participants available at the specified time points were analyzed.

Change From Baseline in Vital Signs-Systolic and Diastolic Blood Pressure

HR, maximum post baseline

HR, minimum post baseline

Change From Baseline in Vital Signs-Pulse Rate

Temperature, max.post baseline

Temperature, min.post baseline

Change From Baseline in Temperature

RR, maximum post baseline

RR, minimum post baseline

Safety population. Only those participants available at the specified time-points were analyzed.

Change From Baseline in Respiratory Rate (RR)

BUN, Normal to low

BUN, Normal to high

Chloride, Normal to low

Chloride, Normal to high

Free Thyroxine , Normal to low

Free Thyroxine , Normal to high

Free Triiodothyronine, Normal to low

Free Triiodothyronine, Normal to high

Free Triiodothyronine, High to low

Lactate Dehydrogenase, Normal to high

Protein, Normal to low

Protein, Normal to high

TSH, Normal to low

TSH, Normal to high

Safety population. Only those participants available at the specified time points we re analyzed.

Number of Participants With Shift From Baseline in by High/Low Flag for Serum Chemistry- Ungraded

Alanine aminotransferase, G0 to G3

Alanine aminotransferase, G0 to G4

Albumin, G0 to G3

Albumin, G1 to G3

Albumin G2 to G3

Alkaline phosphatase, G0 to G3

Amylase, G0 to G3

Aspartate aminotransferase, G1 to G3

Aspartate aminotransferase, G0 to G4

Aspartate aminotransferase, G2 to G3

Bilirubin, G0 to G3

Creatinine, G0 to G3

GGT, G1 to G3

GGT, G2 to G3

Phosphate, G0 to G3

Triacylglycerol Lipase, G0 to G3

Triacylglycerol Lipase, G3 to G4

Sodium, G0 to G3

Sodium, G1 to G3

GSK1363089, Intermittent 5 & 9 Dosing

Safety population. Only those participants available at the specified time points were analyzed .

Number of Participants With Shift From Baseline in Serum Chemistry- Graded

Basophils, Normal to high

Eosinophils, Normal to low

Eosinophils, Normal to high

Erythrocytes, Normal to low

Erythrocytes, Normal to high

Erythrocytes, Low to high

Hematocrit, Normal to low

Hematocrit, Normal to high

Monocytes, Normal to low

Monocytes, Normal to high

Number of Participants With Shift From Baseline by High/Low Flag for Hematology Paramaters

Bilirubin, normal to abnormal

Ketones, normal to abnormal

Nitrites, normal to abnormal

Occult blood, normal to abnormal

pH, normal to abnormal

Protein, normal to abnormal

Specific gravity, normal to abnormal

Urobilinogen, normal to abnormal

Safety population. Only those participants available at the specified timepoints were reported.

Number of Participants With Grade Shift for Urinalysis Parameters

Hemoglobin, G2 to G3

Lymphocytes, G2 to G3

Platelet, G0 to G4

Number of Participants With Shift From Baseline by Grade for Hematology Parameters

Subsequent Chemotherapy

Subsequent Radiation therapy

Other

Number of Participants Who Required Concomitant Medications

Median Progression Free Survival (PFS) of GSK1363089

Evaluable population. Only those participants available at the specified time-points were analyzed.

Duration of Stable Disease of GSK1363089

The eligible participants in this arm were administered GSK1363089 at 80 mg daily for treatment period of 8 weeks. Participants fasted 2 hours before the dose, followed by a glass of water (after the intake of GSK1363089) and continued to fast 1 hour after each dose. The enrollment in this cohort was started until the enrollment completion in the Intermittent 5 \& 9 dosing arm

Disease Stabilization Rate of GSK 1363089

Median Duration of Overall Survival (OS)of GSK1363089

The eligible participants in this arm were administered GSK1363089 at 240 milligram (mg) per dosing day orally, on 5 days on and 9 days off cycle every 2 weeks for treatment period of 8 weeks. Participants fasted 2 hours before the dose, followed by a glass of water (after the intake of GSK1363089) and continued to fast 1 hour after each dose

Overall Study

SGX523 Capsules

Michael Gordon, MD

Ramesh Ramanathan, MD

SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer. This Phase I trial is studying the safety, side effects, and best dose of SGX523 when given to patients with advanced cancer, and how well it inhibits MET activity in tumors.

Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors

A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, Ona Twice Daily, Interrupted Schedule in Patients With Advanced Cancer

SGX Pharmaceuticals, Inc.

Terry Rugg, MD

Lee Rosen, MD

Howard Burris, MD

A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer

Sarcoma

Soft Tissue Sarcoma

Endothelial Growth Factors

Mitogens

Combination pazopanib plus ARQ197 at doses established during escalation phase

Vascular endothelial growth factor (VEGFR) inhibitor

Pazopanib

Hepatocyte growth factor receptor (mesenchymal-epithelial transition factor \[c-MET\]) inhibitor

ARQ 197

Alice P Chen, M.D.

Background:

- Pazopanib is an anticancer drug that blocks the growth of new blood vessels in tumors. It has been approved to treat renal cell cancer and soft tissue sarcomas in patients who have received prior chemotherapy. ARQ 197 (Tivantinib) is an experimental drug that blocks a protein called mesenchymal-epithelial transition factor (c-MET), which cancer cells need to grow. Studies suggest that some drugs that block blood vessel growth can increase the production of c-MET in tumors, which helps cancer cells keep growing. Blocking both blood vessel growth and c-MET with pazopanib and ARQ 197 may help kill cancer cells faster. This study will use these drugs to treat solid tumors that have not responded to earlier treatments.

Objectives:

- To test the safety and effectiveness of pazopanib and ARQ 197 for advanced solid tumors.

Eligibility:

- Individuals at least 18 years of age who have advanced solid tumors that have not responded to earlier treatments.

Design:

* Participants will be screened with a physical exam and medical history. They will also have blood and urine tests, and imaging studies.
* The study drugs will be given in 4-week cycles of treatment. Participants will take pazopanib once a day and ARQ 197 twice a day by mouth. Some participants will start with pazopanib or ARQ 197 alone for the first week. Then they will take both drugs together for the rest of the study.
* Participants will be monitored with frequent blood tests and imaging studies. Optional tumor samples may be collected during different treatment cycles.

Background:

* Vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) signal transduction pathways have synergistic effects on promoting angiogenesis and growth factor expression. Hypoxia caused by treatment with VEGF inhibitors results in the upregulation of mesenchymal-epithelial transition factor (c-MET), the receptor for HGF. In a mouse model, combined blockade of VEGFR and c-MET significantly prolonged survival compared with inhibition of either target alone.
* We hypothesize that co-administration of the putative hepatocyte growth factor receptor (MET) inhibitor ARQ 197 (Tivantinib) will prevent the adaptive response to hypoxia resulting from treatment with the VEGFR inhibitor pazopanib, and conversely, that co-administration of pazopanib will prevent the effect of increased VEGF and reduced thrombospondin 1 in tumors after treatment with ARQ 197. Therefore, the combination of these agents may result in improved antitumor effects.

Objectives:

* Establish the safety and tolerability of the combination of pazopanib with ARQ 197 in patients with refractory advanced solid tumors.
* Establish the maximum tolerated dose (MTD) of the combination of pazopanib with ARQ 197 in patients with refractory advanced solid tumors.
* Evaluate changes in MET and phospho-MET following treatment with pazopanib and ARQ 197 in patients with refractory advanced solid tumors.
* Determine the pharmacokinetics (PK) of pazopanib and ARQ 197.
* Determine and compare levels of total MET, phospho MET, Hypoxia-Inducible Factor (HIF)-1, and epithelial-mesenchymal transition markers (e-cadherin, beta catenin) in tumor biopsy samples prior to and following administration of the study drugs.
* Determine and compare levels of circulating levels of hepatocyte growth factor (HGF), soluble MET (sMET), vascular endothelial growth factor A (VEGF-A), and soluble vascular endothelial growth factor receptor 2 (VEGFR2) (sVEGFR2) prior to and following administration of the study drugs.
* Determine polymorphisms in the cytochrome P450 2C19 (CYP2C19) and correlate these with the observed toxicities, and the pharmacokinetics (PK) of ARQ 197.
* Evaluate antitumor activity of the combination of pazopanib and ARQ 197 in patients with refractory advanced solid tumors.

Eligibility:

-Adults with advanced, refractory solid tumors. Patients enrolling in the expansion cohorts must have advanced sarcoma, gastric cancer, and MET-expressing malignancies, have disease amenable to biopsy, and be willing to undergo pre-and post-treatment biopsies.

Study Design:

* ARQ 197 will be administered orally twice daily and pazopanib orally once daily, in 28-day cycles.
* Dose escalation will proceed using the traditional 3+3 design.
* Once the maximum tolerated dose (MTD) is established, an additional cohort will be accrued for pharmacodynamic (PD) studies in tumor biopsies (required in the expansion phase). For the first week, patients will receive pazopanib alone to compare PK and PD results; combination therapy will be given from week 2 onwards.

Pazopanib and ARQ 197 for Advanced Solid Tumors

Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.

Core tumor biopsies were collected from participants with advanced malignancies. Analyses was performed by epithelial-mesenchymal transition immunofluorescence assay (EMT-IFA) for changes in E-cadherin (E+), vimentin(V+), and mixed V+E+ phenotypes. The small imaging pixel size (0.25 µm\^2)of the IFA relative to the dimensions of the cross sectional areas of tumor (ranging from 75 to 500 µm\^2 in parotid, prostate, colon, and ovarian cancers) allowed us to quantify individual areas of V+ and E+ staining as well as areas of colocalized E+V+ staining within single cells. The assay reports the change in log10(V/E) vratios. The log10(V/E) ratio was determined pre-treatment and in day 8 biopsies and the reported values indicate the change between the two time points. Each value in the table as currently written reflects the change in log10(V/E) ratios between pre- and post-treatment E-cadherin and vimentin values. The full range values indicate the range of changes observed for individual pt.

The highest Grade 3 or 4 adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Grade 3 is severe, and Grade 4 is life threatening.

MET or phospho-MET levels (in fmol) normalized to the amount of total protein in a sample (in mg).

National Cancer Institute (NCI)

Principal Investigator

Cycle=28 days,Pazopanib: 400 mg by mouth (PO) every day (QD) ,ARQ 197: 120 mg PO twice a day (BID)

Dose Level (DL) 1: Pazopanib (Paz): 400 mg & ARQ 197: 120 mg

Cycle=28 days,Pazopanib: 600 mg by mouth (PO) every day (QD),ARQ 197: 120 mg by mouth (PO) twice a day (BID)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors	NCT00743067	Solid Tumours	GSK1363089 (for...	18 Years -	GlaxoSmithKline
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors	NCT00742131	Solid Tumours	GSK1363089	18 Years -	GlaxoSmithKline
Study of GSK1363089 in Metastatic Gastric Cancer	NCT00725712	Neoplasms, Gast...	GSK1363089 (for...	18 Years -	GlaxoSmithKline
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors	NCT00743067	Solid Tumours	GSK1363089 (for...	18 Years -	GlaxoSmithKline
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors	NCT00607399	Advanced Cancer	SGX523 Capsules	18 Years -	SGX Pharmaceuticals, Inc.
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors	NCT00606879	Advanced Cancer	SGX523 Capsules	18 Years -	SGX Pharmaceuticals, Inc.
Pazopanib and ARQ 197 for Advanced Solid Tumors	NCT01468922	Solid Tumor	Pazopanib ARQ 197	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)
Pazopanib and ARQ 197 for Advanced Solid Tumors	NCT01468922	Solid Tumor	Pazopanib ARQ 197	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors	NCT00607399	Advanced Cancer	SGX523 Capsules	18 Years -	SGX Pharmaceuticals, Inc.
A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.	NCT00651365	Neoplasms	JNJ-38877605	18 Years -	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pazopanib and ARQ 197 for Advanced Solid Tumors	NCT01468922	Solid Tumor	Pazopanib ARQ 197	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)

Spots Global Cancer Trial Database for met inhibitor